These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24614668)

  • 1. Ropinirole-induced Pisa syndrome in Parkinson disease.
    Galati S; Möller JC; Städler C
    Clin Neuropharmacol; 2014; 37(2):58-9. PubMed ID: 24614668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy.
    Cannas A; Solla P; Floris G; Tacconi P; Serra A; Piga M; Marrosu F; Marrosu MG
    J Neurol; 2009 Mar; 256(3):390-5. PubMed ID: 19319462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 4. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
    Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
    Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
    Arai M
    Neuro Endocrinol Lett; 2012; 33(7):680-3. PubMed ID: 23391874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teaching NeuroImages: Pisa syndrome in Parkinson disease.
    Rossi M; Merello M
    Neurology; 2014 Nov; 83(19):e177. PubMed ID: 25367063
    [No Abstract]   [Full Text] [Related]  

  • 7. Pisa syndrome in Parkinson disease: An observational multicenter Italian study.
    Tinazzi M; Fasano A; Geroin C; Morgante F; Ceravolo R; Rossi S; Thomas A; Fabbrini G; Bentivoglio A; Tamma F; Cossu G; Modugno N; Zappia M; Volontè MA; Dallocchio C; Abbruzzese G; Pacchetti C; Marconi R; Defazio G; Canesi M; Cannas A; Pisani A; Mirandola R; Barone P; Vitale C;
    Neurology; 2015 Nov; 85(20):1769-79. PubMed ID: 26491088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE; Pahwa R
    Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
    Razmy A; Lang AE; Shapiro CM
    Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.
    Dusek P; Busková J; Růzicka E; Majerová V; Srp A; Jech R; Roth J; Sonka K
    Clin Neuropharmacol; 2010 Jul; 33(4):186-90. PubMed ID: 20661025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Camptocormia Induced by a Dopaminergic Agonist.
    Mano T
    Clin Neuropharmacol; 2018; 41(2):70-72. PubMed ID: 29401068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
    Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; Stocchi F
    Clin Neuropharmacol; 1998; 21(3):169-75. PubMed ID: 9617508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists.
    Klawans HL; Paleologos N
    Clin Neuropharmacol; 1986; 9(3):298-302. PubMed ID: 3719575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
    Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
    [No Abstract]   [Full Text] [Related]  

  • 17. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Camptocormia or Pisa syndrome in multiple system atrophy.
    Sławek J; Derejko M; Lass P; Dubaniewicz M
    Clin Neurol Neurosurg; 2006 Oct; 108(7):699-704. PubMed ID: 16112411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second generation of dopamine agonists: pros and cons.
    Rabey JM
    J Neural Transm Suppl; 1995; 45():213-24. PubMed ID: 8748628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.